This clinical trial is focused on studying a type of bladder cancer known as muscle-invasive bladder cancer. The study is investigating the effectiveness and safety of a treatment plan that includes a combination of medications. Initially, patients will receive a combination of Durvalumab, Gemcitabine, and Cisplatin as a pre-surgery treatment. After surgery, patients will continue with Durvalumab alone as a follow-up treatment. Durvalumab is a type of medication that helps the immune system fight cancer cells, while Gemcitabine and Cisplatin are chemotherapy drugs that work by stopping the growth of cancer cells.

The purpose of this study is to determine how well this treatment plan works and how safe it is for patients with muscle-invasive bladder cancer. The study will involve several stages, starting with the combination treatment before surgery, followed by surgery, and then continuing with Durvalumab alone. Patients will receive these treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor patients over a period to assess the treatment’s effectiveness and any side effects.

Participants in the study will be closely observed to see how their cancer responds to the treatment and to ensure their safety throughout the process. The study aims to provide valuable information that could improve treatment options for people with muscle-invasive bladder cancer in the future.